Intellia Therapeutics (NTLA) Liabilities and Shareholders Equity (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Liabilities and Shareholders Equity data on file, last reported at $758.8 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 23.06% year-over-year to $758.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 billion (down 24.59% YoY) and the FY2025 annual result came in at $842.1 million, down 29.29% from the prior year.
• Liabilities and Shareholders Equity slipped to $758.8 million in Q1 2026 per NTLA's latest filing, from $842.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.5 billion in Q4 2022 and bottomed at $758.8 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $1.2 billion (2024), against an average of $1.1 billion.
• The widest annual swing landed in 2022, when Liabilities and Shareholders Equity surged 67.78%; it then slipped 29.29% in 2025.
• Tracing NTLA's Liabilities and Shareholders Equity over 5 years: stood at $1.5 billion in 2022, then retreated by 14.42% to $1.3 billion in 2023, then decreased by 8.45% to $1.2 billion in 2024, then fell by 29.29% to $842.1 million in 2025, then declined by 9.9% to $758.8 million in 2026.
• Per Business Quant, the three latest NTLA Liabilities and Shareholders Equity figures stand at $758.8 million (Q1 2026), $842.1 million (Q4 2025), and $925.3 million (Q3 2025).

Peer Comparison